Sugi Predict

Sugi Predict / Compounds / SCHEMBL25048664

SCHEMBL25048664

SCHEMBL25048664

CCOc1cc(C(=O)O)cc2[nH]ncc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.46
▸ POLB P06746 3/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ IDO1 P14902 2/20 0.43
▸ TDO2 P48775 1/20 0.43
▸ MAPT P10636 1/20 0.41
▸ ALPL P05186 2/20 0.40
▸ CASP6 P55212 1/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ MRGPRX4 Q96LA9 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29835228 1.00 TSHR (0.46) TSHRPOLBALOX15HTTIDO1
SCHEMBL25048663 0.86 TDO2 (0.49) TSHRTDO2MAPTALPLMEN1
SCHEMBL2671673 0.84 CA12 (0.50) TSHRHTTIDO1TDO2KMT2A
SCHEMBL1144882 0.77 TSHR (0.46) TSHRPOLBALOX15HTTMAPT
SCHEMBL17440906 0.76 IDO1 (0.51) IDO1TDO2CYP2C9
SCHEMBL1723345 0.75 HSD17B2 (0.49) TDO2MAPTMEN1KMT2AL3MBTL1
SCHEMBL4407859 0.74 METAP2 (0.42) TDO2MAPTMEN1KMT2ANPC1
SCHEMBL1759083 0.72 TTR (0.46) TSHRPOLBIDO1TDO2CASP6
SCHEMBL3711029 0.72 PTPN6 (0.49) TSHRPOLBALOX15IDO1TDO2
SCHEMBL20610631 0.72 IDO1 (0.48) IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435043-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2025-10-07 — — US disclosed
US-12421196-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2025-09-23 — — US disclosed
US-12215087-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2025-02-04 — — US disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 — — US disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 — — US disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 — — US disclosed
US-20240059659-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-22 — — US disclosed
US-20240051923-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-15 — — US disclosed
EP-4313302-A1 INHIBITORS OF NLRP3 INFLAMMASOME Bioage Labs, Inc. (US) 2024-02-07 — — EP disclosed
CN-117157278-A Inhibitors of NLRP3 inflammasome 柏奥艾奇实验室公司 2023-12-01 — — CN disclosed
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-11-16 — — US disclosed
US-11708334-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-25 — — US disclosed
US-11708334-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-25 — — US disclosed
US-11708334-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-25 — — US disclosed
US-11702391-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-18 — — US disclosed
US-11702391-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-18 — — US disclosed
US-11702391-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-18 — — US disclosed
US-20230051130-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-02-16 — — US disclosed
US-20230051130-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-02-16 — — US disclosed
US-20220324812-A1 INHIBITORS OF NLRP3 INFLAMMASOME HitGen, Inc. (CN) 2022-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708334-B2 Inhibitors of NLRP3 inflammasome NLRP3, NLRP1, PYCARD TSHR 4615/4885POLB 2747/4885ALOX15 560/4885
US-20240059659-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-20240051923-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-12215087-B2 Inhibitors of NLRP3 inflammasome NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-12421196-B2 Inhibitors of NLRP3 inflammasome NLRP3, NLRP1, PYCARD TSHR 4615/4885POLB 2747/4885ALOX15 560/4885
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-11702391-B2 Inhibitors of NLRP3 inflammasome NLRP3, CASP1, PYCARD TSHR 4572/4885POLB 2241/4885ALOX15 417/4885
US-20230051130-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-20220324812-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 TSHR 4549/4885POLB 2125/4885ALOX15 580/4885
US-12435043-B2 Inhibitors of NLRP3 inflammasome NLRP3, NLRP1, PYCARD TSHR 4615/4885POLB 2747/4885ALOX15 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.